For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Advaxis, Inc.

USPTO Granted Patents = 20

CIPO Patents = 6

EPO Patents = 5

Forward Citations = 188

Loading Chart...

Loading Chart...

22 inventors (with patents filed for the assignee):

Anu Wallecha (10 out of 10 patents)

Yvonne Paterson (9 out of 45 patents)

Vafa Shahabi (7 out of 7 patents)

4. John Rothman (6 out of 23 patents)

5. Robert Petit (6 out of 6 patents)

6. Paulo Cesar Maciag (4 out of 13 patents)

7. Reshma Singh (3 out of 15 patents)

8. Michael F Princiotta (3 out of 3 patents)

9. Melissa Gosse (2 out of 3 patents)

10. David Fela (2 out of 2 patents)

11. Mike Grace (2 out of 2 patents)

12. Matthew Seavey (2 out of 11 patents)

13. Donald A Harn, Jr (2 out of 7 patents)

14. Nicola Mason (1 out of 6 patents)

15. Rodolfo Fleury Perini (1 out of 2 patents)

20 patents: Sort by Forward Citations

1. 12239738 - Compositions and methods for lyophilization of bacteria or listeria strains (2025-03-04),

2. 11897927 - Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof (2024-02-13),

3. 11702664 - Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof (2023-07-18),

4. 11446369 - Compositions and methods comprising KLK3 or FOLH1 antigen (2022-09-20),

5. 11179339 - Compositions and methods for lyophilization of bacteria or listeria strains (2021-11-23),

6. 10900044 - Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof (2021-01-26),

7. 10258679 - [object Object] (2019-04-16),

8. 10143734 - Biomarker directed multi-target immunotherapy (2018-12-04),

9. 10064898 - Listeria-based adjuvants (2018-09-04),

10. 10058599 - [object Object] (2018-08-28),

11. 9907849 - Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer (2018-03-06),

12. 9650639 - Dual delivery system for heterologous antigens (2017-05-16),

13. 9644212 - Dual delivery system for heterologous antigens (2017-05-09),

14. 9549973 - Compositions and methods comprising KLK3 or FOLH1 antigen (2017-01-24),

15. 9499602 - Non-hemolytic LLO fusion proteins and methods of utilizing same (2016-11-22),

Advaxis, Inc. is a clinical-stage biotechnology company developing innovative immunotherapies for cancer treatment. Their unique approach leverages the power of the body's immune system to selectively target and attack cancer cells, potentially offering better outcomes for patients. Through their proprietary platform, Advaxis aims to revolutionize cancer treatment by developing safe and effective immunotherapies. For more information about Advaxis and their groundbreaking advancements, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

20 Patents

#42 in Princeton, NJ

#623 in New Jersey

#15,856 in US

#30,316 in the World

Princeton, NJ, United States of America

Advaxis, Inc.

Forward Citations = 188

22 inventors:

Anu Wallecha (10 out of 10 patents)

Yvonne Paterson (9 out of 45 patents)

Vafa Shahabi (7 out of 7 patents)

4. John Rothman (6 out of 23 patents)

5. Robert Petit (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…